1. Home
  2. GCTK vs RDHL Comparison

GCTK vs RDHL Comparison

Compare GCTK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • RDHL
  • Stock Information
  • Founded
  • GCTK 2001
  • RDHL 2009
  • Country
  • GCTK United States
  • RDHL Israel
  • Employees
  • GCTK N/A
  • RDHL N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • RDHL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GCTK Health Care
  • RDHL Health Care
  • Exchange
  • GCTK Nasdaq
  • RDHL Nasdaq
  • Market Cap
  • GCTK 7.6M
  • RDHL 8.6M
  • IPO Year
  • GCTK N/A
  • RDHL N/A
  • Fundamental
  • Price
  • GCTK $0.24
  • RDHL $6.99
  • Analyst Decision
  • GCTK
  • RDHL
  • Analyst Count
  • GCTK 0
  • RDHL 0
  • Target Price
  • GCTK N/A
  • RDHL N/A
  • AVG Volume (30 Days)
  • GCTK 557.4K
  • RDHL 21.2K
  • Earning Date
  • GCTK 11-14-2024
  • RDHL 12-27-2024
  • Dividend Yield
  • GCTK N/A
  • RDHL N/A
  • EPS Growth
  • GCTK N/A
  • RDHL N/A
  • EPS
  • GCTK N/A
  • RDHL N/A
  • Revenue
  • GCTK N/A
  • RDHL $3,707,000.00
  • Revenue This Year
  • GCTK N/A
  • RDHL $224.90
  • Revenue Next Year
  • GCTK N/A
  • RDHL $82.69
  • P/E Ratio
  • GCTK N/A
  • RDHL N/A
  • Revenue Growth
  • GCTK N/A
  • RDHL N/A
  • 52 Week Low
  • GCTK $0.20
  • RDHL $6.35
  • 52 Week High
  • GCTK $4.95
  • RDHL $43.50
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 23.92
  • RDHL 42.91
  • Support Level
  • GCTK $0.20
  • RDHL $7.09
  • Resistance Level
  • GCTK $0.32
  • RDHL $7.44
  • Average True Range (ATR)
  • GCTK 0.03
  • RDHL 0.53
  • MACD
  • GCTK 0.06
  • RDHL -0.03
  • Stochastic Oscillator
  • GCTK 24.45
  • RDHL 12.36

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Share on Social Networks: